ASCO 2014 – Immuno-Oncology

First Trial Assessing Nivolumab in Platinum-Resistant Ovarian Cancer

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Phase 2 Trial of Nivolumab in Metastatic Renal Cell Carcinoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Phase 2 Trial of Nivolumab and VEGF Inhibitors in First-Line Metastatic Renal Cell Carcinoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

MPDL3280A, an Anti-PD-L1 Monoclonal Antibody, in Metastatic Bladder Cancer

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Pharmacokinetics of MEDI4736, an Anti-PD-L1 Monoclonal Antibody, in Advanced Solid Tumors

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Immuno-Oncology: The New Frontier?

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Ipilimumab Combined with Cytotoxic Chemotherapy in Metastatic Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Doublets and Triple Combinations in Metastatic Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Stereotactic Radiosurgery and Ipilimumab for Melanoma Brain Metastases

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Peginterferon alfa-2b Combined with Ipilimumab for Advanced Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Page 2 of 3

1
2
3